Literature DB >> 17805054

Ras pathway activation in malignant mesothelioma.

Manish R Patel1, Blake A Jacobson, Arpita De, Sandra P Frizelle, Pasi Janne, Saritha C Thumma, Brian A Whitson, Faris Farassati, Robert A Kratzke.   

Abstract

INTRODUCTION: Mutations in Ras family genes are rare in malignant mesothelioma. The role of activation of the Ras signaling pathway in the pathogenesis of mesothelioma is not clear.
METHODS: We studied the activation status of the Ras pathway and the status of other Ras-associated kinases in a panel of human mesothelioma cell lines. In addition, we tested the effect of inhibition of several kinase pathways on mesothelioma cell proliferation. The potential role of kinase signaling on the regulation of cap-dependent translation was also studied.
RESULTS: In general, Ras-guanosine triphosphate (GTP) was higher in mesothelioma cell lines when compared with a nontransformed mesothelial cell line (LP9). Furthermore, known Ras effectors such as extracellular-regulated kinase 1/2, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase were found to be active in most of the mesothelioma cell lines tested. Exposure to specific inhibitors of extracellular-regulated kinase 1/2 (U0126) and c-Jun N-terminal kinase (SP600125) significantly decreased the proliferation of H2596 and H2373 cells compared with mock-treated cells. SP600125-mediated c-Jun N-terminal kinase inhibition, but not extracellular-regulated kinase 1/2 inhibition, resulted in a decrease in phosphorylation of 4E-BP1, consequently decreasing cap-dependent activation.
CONCLUSIONS: These experiments provide a rationale for targeting Ras and associated signaling pathways in mesothelioma and also suggest cap-dependent translation as one mechanism by which Ras induces proliferation in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805054     DOI: 10.1097/JTO.0b013e31811f3aab

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.

Authors:  Manish R Patel; Ahad A Sadiq; Joe Jay-Dixon; Tanawat Jirakulaporn; Blake A Jacobson; Faris Farassati; Peter B Bitterman; Robert A Kratzke
Journal:  Int J Oncol       Date:  2011-11-04       Impact factor: 5.650

2.  Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.

Authors:  Manish R Patel; Blake A Jacobson; Holly Belgum; Ahmad Raza; Ahad Sadiq; Jeremy Drees; Hengbing Wang; Joseph Jay-Dixon; Ryan Etchison; Mark J Federspiel; Stephen J Russell; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

3.  Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.

Authors:  Manish R Patel; Joe Jay-Dixon; Ahad A Sadiq; Blake A Jacobson; Robert A Kratzke
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

4.  Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Authors:  Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2014-04-09       Impact factor: 3.850

5.  Dysregulation of microRNAs and tRNA-derived ncRNAs in mesothelial and mesothelioma cell lines after asbestiform fiber exposure.

Authors:  Alfredo Pulvirenti; Carla Loreto; Veronica Filetti; Alessandro La Ferlita; Antonio Di Maria; Venera Cardile; Adriana C E Graziano; Venerando Rapisarda; Caterina Ledda
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

6.  Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense.

Authors:  Yong Y Kim; Linda Von Weymarn; Ola Larsson; Danhua Fan; Jon M Underwood; Mark S Peterson; Stephen S Hecht; Vitaly A Polunovsky; Peter B Bitterman
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

7.  Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.

Authors:  Ahad A Sadiq; Manish R Patel; Blake A Jacobson; Marco Escobedo; Keith Ellis; Lisa M Oppegard; Hiroshi Hiasa; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2009-01-10       Impact factor: 3.850

Review 8.  DNA repair and damage pathways in mesothelioma development and therapy.

Authors:  Faezeh Malakoti; Niloufar Targhazeh; Erfan Abadifard; Reza Zarezadeh; Sahar Samemaleki; Zatollah Asemi; Simin Younesi; Reza Mohammadnejad; Seyed Hadi Hossini; Ansar Karimian; Forough Alemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-05-02       Impact factor: 6.429

9.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.

Authors:  Zeeshan Ahmad; Blake A Jacobson; Mitchell W McDonald; Nicolas Vattendahl Vidal; Gabriel Vattendahl Vidal; Sierra Chen; Maxwell Dillenburg; Aniekan M Okon; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.